,

BCI Pharma is delighted to share its latest results from three preclinical oncology studies

BCI Pharma, in collaboration with Mithra Women’s Health, has demonstrated the anti-tumor activity of its CSF1R inhibitors in several cancer models. Significant tumor regression was observed either alone or in combination with a checkpoint inhibitor leading to a complete sustained tumor regression in 50% of the animals in a triple negative breast cancer model, a very aggressive form of breast cancer. These compelling results demonstrate the huge potential of BCI CSF1R inhibitors in cancer and reinforce the partnership between the two companies.

Follow the link to read Mithra’s press release

/by

Mithra recognizes the high value of the partnership with BCI Pharma

Mithra Women’s Health, a BCI Pharma’s research partner, recognizes the high value of the partnership and considers as a top priority.

Follow the link to read Mithra’s press release

/by
,

BCI Pharma is thrilled to announce positive preclinical results for its CSF1R inhibitors

BCI Pharma is delighted to announce preclinical studies confirmed the broad therapeutic potential of its CSF1R inhibitors. These meaningful and compelling preclinical data come from a fruitful partnership with Mithra Women’s Health and cover medical areas for which unsatisfied therapeutic needs persist including cancer, endometriosis and inflammatory disorders.

Follow the link to read Mithra’s press release.

/by

The newspaper “L’Echo” talks about BCI Pharma

Follow the link to read the full article

/by

BCI Pharma signs a strategic partnership with Mithra

BCI Pharma and Mithra will start a collaboration to deliver new therapy for women! Mithra acquires the rights relating to BCI development program on innovative inhibitors of CSF1R kinase indicated for the treatment of female cancers and endometriosis. Press release

/by

BCI Pharma obtains a grant from the Ministery of Economy of Belgium (DG06)

BCI Pharma is delighted to communicate that the company has received a grant from the DG06 (Belgium) to financially support its second research programm.

/by

BCI Pharma appoints Didier Malherbe as chairman of board of directors

BCI Pharma is proud to announce that Didier Malherbe accepted his nomination as board chairman. Didier will reinforce BCI structure, participate in BCI development phase and connect to more pharma experts.

/by

BCI Pharma is very proud to announce that a Scientific Advisory Board (SAB) has been set up

BCI Pharma is proud to announce that the company set up a scientific advisor board with experts in neuropathic pain (G. Skouteris and F. Bernhard) and translational function (M. Martiens – Toxicology, G. Mueller – Kinase research).

/by